Margarida Serra’s team from the Instituto de Biologia Experimental e Tecnológica has potentially improved the development of liver disease treatments by controlling the oxygen levels in bioreactors to produce more hepatocyte-like cells (HLCs). Current methods generate low numbers of HLCs, but the research found that reducing oxygen levels to 4% boosts number and differentiation of HLCs, setting the stage for future liver disease treatments.
BioAgilytix Makes Multi-Million-Dollar Investments in LC/MS Capabilities
Officials at BioAgilytix say the company has advanced its growth strategy with multi-million-dollar investments in liquid chromatography–mass spectrometry (LC/MS) capabilities, including new platforms and expanded
